首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Universal Haplotype-Based Noninvasive Prenatal Testing for Single Gene Diseases
【24h】

Universal Haplotype-Based Noninvasive Prenatal Testing for Single Gene Diseases

机译:基于通用单倍型的单基因疾病无创产前检测

获取原文
           

摘要

BACKGROUND: Researchers have developed approaches for the noninvasive prenatal testing of single gene diseases. One approach that allows for the noninvasive assessment of both maternally and paternally inherited mutations involves the analysis of single nucleotide polymorphisms (SNPs) in maternal plasma DNA with reference to parental haplotype information. In the past, parental haplotypes were resolved by complex experimental methods or inferential approaches, such as through the analysis of DNA from other affected family members. Recently, microfluidics-based linked-read sequencing technology has become available and allows the direct haplotype phasing of the whole genome rapidly. We explored the feasibility of applying this direct haplotyping technology in noninvasive prenatal testing.METHODS: We first resolved the haplotypes of parental genomes with the use of linked-read sequencing technology. Then, we identified SNPs within and flanking the genes of interest in maternal plasma DNA by targeted sequencing. Finally, we applied relative haplotype dosage analysis to deduce the mutation inheritance status of the fetus.RESULTS: Haplotype phasing and relative haplotype dosage analysis of 12 out of 13 families were successfully achieved. The mutational status of these 12 fetuses was correctly classified.CONCLUSIONS: High-throughput linked-read sequencing followed by maternal plasma-based relative haplotype dosage analysis represents a streamlined approach for noninvasive prenatal testing of inherited single gene diseases. The approach bypasses the need for mutation-specific assays and is not dependent on the availability of DNA from other affected family members. Thus, the approach is universally applicable to pregnancies at risk for the inheritance of a single gene disease.
机译:背景:研究人员已经开发出了用于单基因疾病的无创产前检测的方法。一种允许对母体和父体遗传突变进行非侵入性评估的方法涉及参考母体单倍型信息来分析母体血浆DNA中的单核苷酸多态性(SNP)。过去,父母的单倍型通过复杂的实验方法或推论方法来解决,例如通过分析其他受影响家庭成员的DNA。近来,基于微流体的连锁阅读测序技术已经变得可用,并允许整个基因组的直接单倍型定相。我们探索了在无创产前检测中应用这种直接单体型技术的可行性。方法:我们首先使用链接阅读测序技术解决了亲本基因组的单体型。然后,我们通过靶向测序鉴定了母体血浆DNA中感兴趣的基因并位于其侧翼的SNP。最后,我们采用相对单倍型剂量分析推导了胎儿的突变遗传状况。结果:成功完成了13个科中12个的单倍型定相和相对单倍型剂量分析。结论:这12个胎儿的突变状态得到了正确的分类。结论:高通量连锁阅读测序以及基于母体血浆的相对单倍型剂量分析代表了一种用于遗传性单基因疾病无创产前检测的简化方法。该方法无需进行突变特异性测定,并且不依赖于其他受影响家庭成员的DNA可用性。因此,该方法普遍适用于有遗传单一基因疾病风险的怀孕。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号